Compare Baxter International Inc (BAX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Veritone Inc — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Veritone Inc trades at $1.07 (market cap $98.53M). The key difference: Baxter International Inc is far larger — about 114.3× Veritone Inc's market cap, and Baxter International Inc pays a 0.92% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| BAX | VERI | |
|---|---|---|
Market Cap | $11.26B | $98.53M |
Sector | Health | Technology |
52-Week High | $29.22 | $8.39 |
52-Week Low | $15.80 | $1.07 |
Enterprise Value | $18.93B | $130.56M |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Veritone (VERI) trades at $1.10, down 6.78% in the last 24 hours, with a bearish technical signal despite oversold RSI readings. The company reported revenue of $92.19 million in 2025 but posted a net loss of $111.73 million, with negative profit margins and cash flow challenges. Recent news highlights multiple class action lawsuits alleging securities fraud, creating significant legal overhangs.
Investment outlook remains highly speculative given persistent losses and legal uncertainties. While analyst consensus shows mixed sentiment with 46% buy ratings, fundamental weaknesses and ongoing litigation pose substantial risks. The stock's current valuation at 0.88x sales offers limited protection against operational challenges and potential legal liabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
